SEC Form 4 · accession 0001638599-17-000373
BeOne Medicines Ltd. · ONC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Julian Baker
Director · 10% Owner
Felix Baker
Director · 10% Owner
BAKER BROS. ADVISORS LP
Director · 10% Owner
Baker Brothers Life Sciences LP
Director · 10% Owner
14159, L.P.
Director · 10% Owner
667, L.P.
Director · 10% Owner
Baker Bros. Advisors (GP) LLC
Director · 10% Owner
Period of report
Apr 19, 2017
Accepted (ET)
Apr 21, 2017 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001651308
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy)F1,F2,F3,F4 | $2.84 | Apr 19, 2017 | A | 399,984 | A | — | Apr 18, 2027 | Ordinary Shares | 399,984 | 399,984 | I |
Explanation of responses
- F1In ordinary shares. Ordinary shares are convertible into American Depositary Shares ("ADS") on a 13:1 basis.
- F2199,992 non-qualified share options ("Share Options") convertible solely into Ordinary Shares of BeiGene, Ltd. (the "Issuer") were granted to Michael Goller, an employee of Baker Bros. Advisors LP (the "Adviser") and 199,992 Share Options were granted to Ranjeev Krishana, an employee of the Adviser in their capacity as directors of the Issuer. The Share Options with a strike price of $2.84 vest in 3 equal annual installments beginning on April 19, 2017 and shall become exercisable in full on the date of the third annual meeting of shareholders following the grant date. The Share Options expire on April 18, 2027. Michael Goller and Ranjeev Krishana serve on the Board of Directors of the Issuer as representatives of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 667, L.P. ("667") and 14159, L.P. ("14159", and together with 667 and Life Sciences, the "Funds").
- F3Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Share Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options (i.e. no direct pecuniary interest).
- F4The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Pursuant to agreements between both Michael Goller and Ranjeev Krishana and the Adviser, the Adviser has investment and dispositive power over the Share Options and any shares received as a result of the exercise of options.
Remarks
Michael Goller and Ranjeev Krishana, employees of Baker Bros. Advisors LP, are directors of BeiGene, Ltd. (the "Issuer"). By virtue of their representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.